Academic Journals Database
Disseminating quality controlled scientific knowledge

Adjuvant Cisplatin-Based Chemotherapy for Elderly Patients with Completely Resected Non-Small Cell Lung Cancer: Review of Current Evidence

ADD TO MY LIST
 
Author(s): Martin Fruh | Frances A Shepherd

Journal: European Journal of Clinical & Medical Oncology
ISSN 1759-8958

Volume: 2;
Issue: 2;
Start page: 63;
Date: 2010;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: non-small cell lung cancer (NSCLC) | elderly | adjuvant | chemotherapy

ABSTRACT
Based on results from randomized phase III studies adjuvant cisplatin-based chemotherapy represents the current standard of care in patients with resected stage IB-III non-small cell lung cancer. A pooled analysis of the five largest cisplatin-based adjuvant chemotherapy trials conducted after 1995 showed an absolute overall survival benefit of 5.4% at five years. Even though almost 50 % of non-small cell lung cancers occur in patients older than 70, this group of patients were under-represented in these studies with less than 10 % falling into this category. We herein review the studies which investigated this subgroup of patients.
RPA Switzerland

Robotic Process Automation Switzerland

    

Tango Rapperswil
Tango Rapperswil